4%). Among them, 3 case were diagnosed with gastrinoma (1.3%). Pancreas was the second most often seen located organ (51/233, 22.9%). Insulinoma accounted for 70.6% (36/51) of pancreatic NETs. According to the 2010 WHO classification criteria: NET G1, 84 cases (37.3%); NET G2, 63 (28.3%); NEC, RG-7388 purchase 71 (31.9%). Pathological characteristics: Expression of CgA were examined in 143 patients using immunohistochemistry staining and the positive rate was 67.1% (96/143). CgA expression
positive rate in pancreatic NETs was the highest (24/26, 92.3%), and that in rectal NETs was 41.9%(13/31). Syn expression were detected in 174 cases (78%), and the Syn positive rate was 96.6% (168/174). CgA, Syn, and NSE were combining detected in 45 cases, positive at least one marker. Endoscopy, ultrasound and CT examination were the most often used tools for diagnosis. Surgical resection as the main ways for the treatment. Conclusion: GEP – NETs usually occur in middle-aged male. The most common involved organ
is stomach, followed by pancreas. NET G1 is the most common pathological type. CgA positive rate in pNET is the highest. CgA, Syn and NSE combining test can improve diagnostic sensitivity. Key Word(s): 1. gastrointestinal ; 2. GEP – NETs; Presenting Author: TOMOTAKA SAITO Additional Authors: KNEJI HIRANO, GYOUTANE UMEFUNE, KEI SAITO, DAI AKIYAMA, SHUHEI KAWAHATA, KAORU TAKAGI, TAKEO WATANABE, RIE UCHINO, NAMINATSU TAKAHARA, TSUYOSHI HAMADA, SUGURU MIZUNO, KOUJI MIYABAYASHI, selleck chemical TAKASHI SASAKI, HIROFUMI KOGURE, NATSUYO YAMAMOTO, YOUSUKE NAKAI, HIROYUKI ISAYAMA, MINORU TADA, KAZUHIKO KOIKE Corresponding Author: TOMOTAKA SAITO Affiliations: Tokyo University Objective: Many patients of unresctable pancreas cancer become pancreatic exocrine dysfunction and secondarily digestion malabsorption. There is few report that reviews whether Pancrelipase improves nutritional condition of patients of unresectable pancreas cancer. We try to reveal short term effects of taking orally of Pncrelipase on patients of unresectable pancreas
cancer. Methods: (1)When start chemotherapy to patients of unresectable pancreas cancer,start taking orally of Pancrelipase at the same time. Measure RVX-208 BMI,serum Albumin (Alb), serum Prealbumin (Prealb), serum Total cholesterol (T. chol) when start taking orally of Pancrelipase and 8weeks after start.23 patients (male-to-female ratio 12:11, mean age 66.8). (2) Administer Pancrelipase to patients of unresectable pancreas cancer who already started chemotherapy. Measure BMI,Alb,Prealb,T. chol. when start taking orally of Pancrelipase and 8weeks after start.18 patinets(male-to-female ratio 6:11,mean age 69.4). (3) Assemble data of Patients of unresectable pancreas cancer who alredy started chemotherapy but not administered Pancrelipase. Measure BMI,Alb,Prealb,T. chol. when start chemotherapy and 8weeks after start.82 patients (male-to-female ratio 49:33,mean age 67.6). Results: In case (1).